NICE Turns Down Avastin For Yet Another Indication In Draft Guidance

This article was originally published in The Pink Sheet Daily

01 Feb 2013
News

Faraz Kermani Faraz.kermani@informa.com

Executive Summary

The U.K.’s NICE issues draft guidance recommending against use of Avastin for first recurrence of platinum-sensitive advanced ovarian cancer, citing evidence and cost-effectiveness issues.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United Kingdom

Related Companies

Roche

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Europe United Kingdom

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS075248

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS075248

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

NICE Turns Down Avastin For Yet Another Indication In Draft Guidance

News

Executive Summary

Related Content

Expanded Colorectal Cancer Claim Moves Avastin Toward Continuous Use

NICE Rejects Roche’s Avastin In Advanced Ovarian Cancer

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert